Spark Therapeutics Inc. (ONCE) Trading 2.1% Higher
Spark Therapeutics Inc. (NASDAQ:ONCE) shares traded up 2.1% on Friday . The stock traded as high as $55.70 and last traded at $54.40, with a volume of 159,993 shares traded. The stock had previously closed at $53.28.
Several research analysts have recently weighed in on the company. Royal Bank Of Canada assumed coverage on Spark Therapeutics in a research report on Tuesday, July 12th. They set an “outperform” rating and a $70.00 price objective for the company. Zacks Investment Research raised Spark Therapeutics from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a research report on Thursday, August 11th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $94.00 price objective on shares of Spark Therapeutics in a research report on Thursday, August 11th. Jefferies Group reaffirmed a “hold” rating on shares of Spark Therapeutics in a research report on Sunday, June 12th. Finally, Cowen and Company reaffirmed a “buy” rating and set a $75.00 price objective on shares of Spark Therapeutics in a research report on Thursday, May 19th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the stock. Spark Therapeutics currently has an average rating of “Hold” and an average price target of $61.20.
The firm’s market cap is $1.68 billion. The stock’s 50 day moving average is $56.69 and its 200-day moving average is $43.88.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by $0.07. During the same quarter in the previous year, the business earned ($0.60) earnings per share. The company had revenue of $1.29 million for the quarter, compared to the consensus estimate of $1.17 million. The company’s revenue for the quarter was up .0% compared to the same quarter last year. Equities research analysts forecast that Spark Therapeutics Inc. will post ($3.94) EPS for the current fiscal year.
In related news, Director Hospital Of Philade Children’s sold 1,000,000 shares of Spark Therapeutics stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $60.90, for a total value of $60,900,000.00. Following the sale, the director now owns 5,768,707 shares of the company’s stock, valued at approximately $351,314,256.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Katherine A. High sold 17,610 shares of Spark Therapeutics stock in a transaction that occurred on Wednesday, August 3rd. The stock was sold at an average price of $60.02, for a total transaction of $1,056,952.20. Following the completion of the sale, the insider now directly owns 246,017 shares in the company, valued at approximately $14,765,940.34. The disclosure for this sale can be found here.
An institutional investor recently raised its position in Spark Therapeutics stock. Schwab Charles Investment Management Inc. increased its position in Spark Therapeutics Inc. (NASDAQ:ONCE) by 3.9% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 34,539 shares of the company’s stock after buying an additional 1,283 shares during the period. Schwab Charles Investment Management Inc. owned about 0.14% of Spark Therapeutics worth $1,565,000 at the end of the most recent quarter.
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.